Input variable | Voriconazole | LAmB |
---|---|---|
Fever without baseline infection | Triangular distribution, 92.03%-96.87%-100% | Triangular distribution, 93.65%-98.58%-100% |
Therapeutic success | Triangular distribution, 24.10%-25.37%-26.64% | Triangular distribution, 28.55%-30.05%-31.55% |
Therapeutic failure | Triangular distribution, 70.90%-74.63%-78.36% | Triangular distribution, 66.45%-69.95%-73.45% |
Death | Triangular distribution, 10.45%-11.00%-11.55% | Triangular distribution, 8.16%-8.59%-9.02% |
Breakthrough infection | Triangular distribution, 2.40%-2.67%-2.94% | Triangular distribution, 6.50%-7.22%-7.94% |
Premature discontinuation | Triangular distribution, 12.30%-13.67%-15.04% | Triangular distribution, 8.66%-9.62%-10.58% |
Persistent fever | Triangular distribution, 65.40%-72.67%-79.94% | Triangular distribution, 67.11%-74.57%-82.03% |
Fever with baseline infection | Triangular distribution, 2.97%-3.13%-3.29% | Triangular distribution, 1.20%-1.42%-1.49% |
Therapeutic success | Triangular distribution, 43.84%-46.15%-48.46% | Triangular distribution, 63.34%-66.67%-70.00% |
Therapeutic failure | Triangular distribution, 51.16%-53.85%-56.54% | Triangular distribution, 31.66%-33.33%-35.00% |
Ward “per diem” | Discrete, 30% at TL193.40 and 70% at TL30.00 | |
ICU length of stay | Log-normal, mean 5 days, standard deviation 2.5 days | |
Overall treatment duration | Log-normal, mean 10 days, standard deviation 2 days | |
Proportion of oral voriconazole use | Triangular distribution, 0-22-50% |